The review assessed the symptomatic efficacy of diacerein in the treatment of osteoarthritis. The authors concluded that diacerein improved symptoms and had reasonable tolerability in knee and hip osteoarthritis. Inadequate information on individual studies and the methods used to deal with the results, and differences between the studies, make it difficult to assess the reliability of the results.
Data extraction
Two reviewers, blind to the authors, publication date and journal, independently extracted the data; a statistician checked the extracted data. Where possible, ITT data were extracted.
Methods of synthesis
How were the studies combined? The studies were grouped by outcome, comparator and timing of the outcome assessment. The individual results were pooled using Glass scores (standardised mean differences) corrected for small sample size bias using exact methods. The inverse normal method was used for statistical assessment (significance level p<0.05), using exact weighting techniques. Pooled results weighted by study quality were presented. Type one error control was based on the Bonferroni-Holm procedure.
How were differences between studies investigated?
The robustness of the results was investigated using two different weighting methods (weighted by sample size and by study quality) for the Glass scores. The heterogeneity assessment was based on identifying non-overlapping two-sided 95% confidence intervals (CIs).
Results of the review
Nineteen RCTs (n=2,637) were included in the review.
The mean Jadad scores varied between 0 and 5 in the documented studies.
The results below are for the Jadad weighted meta-analyses; those for the sample size-weighted meta-analyses were similar.
Diacerein was statistically superior to placebo regarding pain during the active treatment phase (Glass score 1.50, 95% CI: 0.80, 2.20; based on 8 studies) and at the end of the follow-up period (Glass score 2.67, 95% CI: 1.27, 4.07; number of studies unclear).
Diacerein was statistically superior to placebo regarding functional impairment during the active treatment phase (Glass score: 1.49, 95% CI: 0.78, 2.19; based on 8 studies).
Diacerein was not statistically superior to standard treatment (mostly NSAIDs) regarding pain during the active treatment (-0.35, 95% CI: -1.11, 0.4; based on 10 studies), but it was statistically superior at the end of the follow-up period (2.13, 95% CI: 1.32, 2.93; based on 8 studies).
Diacerein was not statistically superior to standard treatment (mostly NSAIDs) regarding function during active treatment (0.12, 95% CI: -0.68, 0.93), but it was statistically superior at the end of the follow-up period (2.58, 95% CI: 1.71, 3.45).
Diacerein was statistically inferior to placebo regarding tolerability ratings (-1.51, 95% CI: -2.21, -0.81; number of studies unclear), but there were no significant differences between diacerein and NSAIDs (0.09, 95% CI: -0.66, 0.85; number of studies unclear).
Authors' conclusions
There is evidence that diacerein has symptomatic efficacy and reasonable tolerability in the treatment of knee and hip 
CRD commentary
The review addressed a clear research question but some of the exact inclusion criteria remained unclear: for example, studies had to fulfil an undefined methodological quality threshold and it was not entirely clear what kind of data a study had to report to be eligible for inclusion. The search was limited in terms of the databases searched and only studies published in selected languages were eligible; a procedure that could have introduced language bias into the review. Efforts were made to locate unpublished data, which helped prevent publication bias. Study quality was assessed and the Jadad scores were integrated in the analysis. There was no information on the drug doses used in the included studies, so the comparability of the studies and equivalence of comparator drugs could not be assessed.
For some analyses it was unclear on which studies (and how many) the results were based. The assessment methods for the outcomes in the individual studies varied widely; it remains unclear whether the pooled results are clinically meaningful or clinically significant. It was not clear how the authors dealt with multiple measures of pain or function reported in the same study. The methods used to measure the patients' tolerability ratings were not examined, which meant it was not possible to adequately evaluate the validity of the results for this outcome. Several of the meta-analysis graphs showed non-overlapping CIs and different directions of effects, indicating the presence of heterogeneity; this suggests that pooled effect sizes might not have been an appropriate summary measure. Potential reasons for differing results among the studies were not explored or discussed. The lack of adequate information on the individual studies and methods used to extract and deal with the results data, as well as differences between the studies, make it difficult to assess the reliability of results.
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